0000902664-17-004371.txt : 20171116 0000902664-17-004371.hdr.sgml : 20171116 20171116114727 ACCESSION NUMBER: 0000902664-17-004371 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171114 FILED AS OF DATE: 20171116 DATE AS OF CHANGE: 20171116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: venBio Select Advisor LLC CENTRAL INDEX KEY: 0001633313 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 171207268 BUSINESS ADDRESS: STREET 1: 120 WEST 45TH STREET STREET 2: SUITE 2802 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 212-937-4975 MAIL ADDRESS: STREET 1: 120 WEST 45TH STREET STREET 2: SUITE 2802 CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOMEDICS INC CENTRAL INDEX KEY: 0000722830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 611009366 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 300 AMERICAN RD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 BUSINESS PHONE: 9736058200 MAIL ADDRESS: STREET 1: 300 AMERICAN ROAD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 4 1 p17-2247form4.xml IMMUNOMEDICS INC X0306 4 2017-11-14 0 0000722830 IMMUNOMEDICS INC IMMU 0001633313 venBio Select Advisor LLC 120 WEST 45TH STREET SUITE 2802 NEW YORK NY 10036 1 0 1 1 See Remarks Common Stock, $0.01 par value per share (the "Common Stock") 2017-11-14 4 P 0 1150000 10.39 A 15889461 I See footnotes Common Stock 2017-11-15 4 P 0 175000 10.97 A 16064461 I See footnotes The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.2 to $10.8403 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth herein. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.6584 to $11.3049 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth herein. The Investment Manager may be deemed a director by deputization of Immunomedics, Inc. (the "Issuer") by virtue of the fact that Dr. Agahazadeh currently serves on the board of directors of the Issuer. venBio Select Advisor LLC, by: /s/ Scott Epstein, its Chief Financial Officer & Chief Compliance Officer 2017-11-15 /s/ Behzad Aghazadeh 2017-11-15